UnitedHealth Group Incorporated (NYSE: UNH), initiation of coverage, Nov 20, 2026
UnitedHealth still trades at a premium its peers and margins cannot support
UnitedHealth insures 48 million Americans and owns the clinics, pharmacies and software those members use. Earnings are recovering, but at peers’ multiple the shares are worth about $266, not $350.
- Our rating
- Sell
- 12-month target
- $297.81
- Price, Nov 18, 2026
- $349.91
- Expected return, with dividend
- −12%
By Penmark Team
What UnitedHealth is now
Mostly an insurer, with earnings now climbing back from a 2025 slump
UnitedHealthcare collects premiums from Medicare, states and employers, then spends much of them at Optum’s own clinics and pharmacies. Premiums were 78.7% of $447.6bn of revenue in 2025.
In 2025 care costs jumped and the medical care ratio hit 89.1%, so adjusted EPS fell 41% to $16.35. We see it rebuilding to $27.35 by 2028.
Shares sum to 100.1% because of rounding. Source: company FY25 10-K.
Source: company filings, Penmark Research estimates.
What you are really buying
The price pays a premium multiple that our analysis does not support
At $349.91, buyers pay 14.9 times our 2027 earnings. Our earnings are slightly above the Street and our audit-rule cost is smaller than the sell-off implied; both add value.
The multiple is what matters. Valuing UnitedHealth like its restated peers takes $94.65 a share off, leaving our $266.36 base value.
Sequential bridge; the audit step compares our 35% probability with full enforcement. Source: Penmark Research estimates.
Where we disagree: the multiple
Restated for growth and returns, peers point to 11.5 times earnings
Bulls see UnitedHealth’s 18.5x five-year average P/E as a floor. We adjust Elevance, Cigna and CVS for UnitedHealth’s 13% growth and 22% forward ROE.
That gives 15.9x, 11.4x and 10.4x, a median of 11.4x. UnitedHealth trades at 15.1x on its own 2027 outlook, so the gap costs $95 a share.
Company 2027 outlook basis. Source: company outlooks, Penmark Research model.
Where we disagree: margins
Margins recover, but not to the old 8.65% level
Bulls treat 2025’s 4.9% margin as a blip before a return to the 8.65% median of 2020 to 2025. We see 6.3% in 2027 and 7.5% by 2030.
The V28 risk-model phase-in, commercial cost trend above 11% and pharmacy rebate pass-through hold margins down. The price implies a 6.4% UnitedHealthcare margin; we model 4.1%.
Source: company filings, Penmark Research estimates.
Where we disagree: the audit rule
The audit sell-off was far bigger than the likely cost
When CMS proposed the CRUSH audit rule, the shares fell $62.11 in two days. Even if fully upheld, the after-tax cost is $11.66 a share.
At a 35% chance of the rule standing, we deduct $4.08. The cash cost was overdone, but lasting policy risk still keeps peers near 11.5x.
After-tax present value of RADV recoveries over 2018 to 2027. Source: CMS-6098-P, Yahoo Finance, Penmark Research model.
The odds
Our middle case sits well below the price
In our middle case, 2027 EPS of $23.52 at 11.5x less audit costs gives $266.36. The good case, with $26.75 EPS at 16.0x and no audit cost, gives $428.07.
The bad case, with $17.18 EPS at 10.5x and the full audit cost, gives $168.75. Weighting the three and rolling forward gives our $297.81 target, a −12.2% total return.
- Good, 25%$26.75 EPS at 16.0x, UnitedHealthcare margin 4.6%, Optum Health 5.0% and the audit rule vacated.
- Middle, 50%$23.52 EPS at 11.5x less a $4.08 audit cost; UnitedHealthcare margin 4.1%.
- Bad, 25%$17.18 EPS at 10.5x less the full $11.66 audit cost; UnitedHealthcare margin 3.0%.
Circle size shows how likely we think each case is. Case values are today’s values; the target rolls the weighted $282.39 forward 12 months. Source: Penmark Research.
What would change our mind
January guidance and April’s cost ratio test our call
Comments on the audit rule close on 19 January, results and 2027 guidance follow on 26 January, and the 2028 Medicare Advantage rates land on 6 April.
We would move to Hold on 2027 EPS guidance above $24.80 with a ratio under 86.5% and peers above 12.1x, or if the price fell below about $341.
Insurers challenge the 2018 to 2027 audit extrapolation.
We expect $2.39 of Q4 EPS, a 91.0% ratio and $23.52 for 2027.
Draft 2028 rates; tight chart-review curbs would cost $1.67 a share.
Locks 2028 bids and rates for Medicare Advantage.
Tests commercial pricing above 11% trend and a 4.0% Optum Health margin.
Inside the full report
What each page covers after the summary on pages 1 and 2. Each opens the full report at that page.
See all 22 pages
- 3Adjusted ROE rebuilds to about 20% in FY27E; our EPS is 1% above consensus
- 4UNH trades at a 61% raw P/E premium to core managed-care peers despite similar growth
- 5MCR swings drove the derating, and peer multiple parity leaves 24% downside to base value
- 6Three debates separate our $266 value from the $350 price; the P/E debate dominates
- 7UnitedHealthcare is Optum’s biggest customer, worth $168bn a year
- 8Vertical integration links $345bn of health plans to $271bn of Optum care and pharmacy
- 9Medicare & Retirement drives 38% of revenue, while Optum generates half of operating profit
- 10Government programmes fund 39% of $5.3tn US health spend, putting CMS at the centre of margins
- 11Scale and Optum integration lift ROE to 22%, while 9M26 UHC margin sits at 4.8%
- 12Top five leaders hold $531m of shares and near-term awards, with 79%–99% equity pay
- 13Management pivoted from $18bn of FY24–25 M&A to deleveraging toward 40% debt-to-capital
- 14UNH trades on MCR surprises, CMS policy rules and Optum Health margins, not market beta
- 15Company news explains 86% of variance, and three topics take 81% of analyst Q&A
- 19Revenue compounded at about 12% over five years, until FY25A MCR ended an 8%–9% margin run
- 20Revenue accelerates from 0.5% in FY26E to 5% by FY30E as margins rebuild to 7.5%
- 21Peer P/E gives a $266 base value; weighted scenarios give our $298 target
- 22Matching $350 requires about an 11% discount rate or a 6.4% UHC margin
- 23Seven milestones through 2027 test UNH’s 15x multiple
- 24Restoring the 8.7% historical median margin (+$108/sh) leads upside risks; unpriced trend (−$41/sh) leads downside
- 25Institutions hold 90% of UNH, and none of 26 analysts rate it Sell
- 26Linked annual financial model (FY25A–FY30E) and nine-quarter operating progression
- 27Non-GAAP reconciliation, glossary, ratio definitions, peer rules and source cut-offs
Penmark Research. This summary draws on our initiation report on UnitedHealth Group Incorporated, published Nov 20, 2026. It is not investment advice. Analyst certification, rating definitions and important disclosures are in the full report.